268 results about "Intraperitoneal injection" patented technology

The invention relates to the field of medical application, in particular to application of nerve-soothing and brain-strengthening liquid to preparation of medicine for treating or preventing chronic fatigue syndrome. According to the invention, the nerve-soothing and brain-strengthening liquid is used for research on treatment or prevention of chronic fatigue syndrome for the first time. By establishing an intraperitoneal injection polyinosinic-cytidylic acid composite swimming induced CFS mouse model and a multi-factor composite stress induced CFS rat model, and by means of an exhaustive swimming experiment, a tail suspension experiment, a mechanical pain threshold, a Bannes maze and a pentobarbital sodium sleep experiment, an endocrine function, an immunologic function, skeletal muscle energy metabolism and other modes are detected, and the skeletal muscle energy metabolism can be detected. It is found that the nerve soothing and brain strengthening liquid can improve the CFS symptoms shown by mice and rats of the two models.

The invention discloses an establishment method and a verification method of a hydrogen peroxide induced mouse autism model, and relates to the technical field of medical biologication.The establishment method of the hydrogen peroxide induced mouse autism model comprises the following steps that a hydrogen peroxide solution is injected into the abdominal cavity of a pregnant mouse, hydrogen peroxide induction is conducted, and the mouse autism model is obtained. And obtaining a hydrogen peroxide induced offspring mouse, namely the mouse autism model. Hydrogen peroxide is used for near intraperitoneal injection of a female mouse during pregnancy, the oxidative stress state of the female mouse during pregnancy and the oxidative stress state of an offspring mouse embryo are induced through independent hydrogen peroxide, and obvious immune response of the female mouse is not caused, so that an ASD mouse model specifically induced by oxidative stress is formed; the obtained ASD offspring mouse has a remarkable ASD phenotype, but does not show obvious dyskinetic disorder.

The invention discloses application of decitabine in preparation of a medicine for resisting vascular calcification, and belongs to the technical field of medical biology. A CKD mouse vascular calcification model is constructed through combination of 5 / 6 nephrectomy and high phosphorus diet (5 / 6NX), and it is observed that the expression level of DNMT3A in model mouse calcified blood vessels is remarkably increased, and the DNA methylation degree is remarkably increased. Based on this, people try to use decitabine to reduce the expression of DNMT, and discover that intraperitoneal injection of decitabine inhibits the expression of DNMT3A in CKD artery blood vessels and osteogenesis-like transdifferentiation of vascular smooth muscle cells, so that CKD-related vascular calcification is effectively relieved.

The invention belongs to the technical field of biology, and particularly relates to application of hepcidin expression quantity in larimichthys crocea liver as larimichthys crocea visceral white-spot disease resistance evaluation index and a construction method. The hepcidin expression quantity in the larimichthys crocea liver is applied as the larimichthys crocea visceral white-spot disease resistance evaluation index. The construction method of the resistance evaluation index comprises the following steps: taking healthy small yellow croaker intraperitoneal injection pseudomonas proteinus strain bacterial liquid, and determining a half lethal dose in 96 hours; the method comprises the following steps: injecting a half lethal dose of bacterial liquid of pseudomonas proteinus strains into the abdominal cavity of healthy small yellow croaker for 96 hours, and after infection, taking different tissues to carry out hepcidin gene expression fluorescent quantitative PCR analysis; a regression model of gene expression quantity and bacterium loading quantity is established through fluorescence quantification, and the relationship between hepcidin expression quantity and disease resistance is constructed. Accurate disease-resistant phenotype information is provided for development of breeding of visceral white-spot disease-resistant improved varieties of the small yellow croakers, the accuracy of disease-resistant breeding is promoted, early detection of diseases is realized, and prevention and treatment of the diseases are effectively guided.

The invention relates to a human recombinant GDF15 protein and application thereof in preparation of drugs for preventing and treating sepsis acute kidney injury, and belongs to the technical field of biological medicines. In order to solve the problem that an effective prevention and treatment scheme for improving SA-AKI by inhibiting oxygen death is lacked in existing clinical and research, the invention provides a human recombinant GDF15 protein of which the coding gene nucleotide sequence is shown as SEQ ID No: 1. Animal experiment results show that by intraperitoneal injection of the human recombinant GDF15 protein, kidney inflammation of sepsis mice can be relieved, and expression of PGAM5 can be down-regulated. Cell experiment results show that when the human recombinant GDF15 protein is given, LPS-induced USF2 increase can be inhibited. The human recombinant GDF15 protein provided by the invention can improve SA-AKI by inhibiting oxygen death and inflammation, provides a new idea and an intervention target for prevention and treatment of SA-AKI, and shows a good clinical application prospect.

The invention discloses an application of a polypeptide Apelin-13 in a medicine for treating psoriasis, in particular to psoriasis-like skin lesion. In an imiquimod (IMQ) cream induced mouse psoriasis model, intraperitoneal injection of Apelin-13 can significantly reduce scale, erythema and skin thickness, and can inhibit proliferation of epithelial spine cells. HE staining and immunohistochemical staining are carried out on the skin tissue of an experimental mouse, and the result shows that Apelin-13 can reduce the expression of the psoriasis marker protein K17, the thickness of the surface layer of the back side skin of the experimental mouse and the downward extension of a spinous layer. Experimental mouse serum ELISA (enzyme-linked immunosorbent assay) detection results show that the Apelin-13 can be used for down-regulating IL-17A (interleukin-17A) which is highly expressed in psoriasis. The polypeptide Apelin-13 can be used as a medicine for treating psoriasis, especially a medicine for treating psoriasis-like skin lesion.

The invention discloses a method for constructing an atrial fibrillation small animal model through succinic acid induction and application, and the method comprises the following steps: in an animal model construction period, enabling a small animal to ingest an aqueous solution containing succinic acid or all pharmaceutically acceptable salts of succinic acid every day, and finishing the modeling period to obtain the animal model. Compared with a traditional angiotensin AngII administration method, the atrial fibrillation small animal model has the advantages that the cost of a medicine for constructing the animal model is lower, the economic benefit is higher, and the atrial fibrillation induction effect is better; the model represents the most common atrial fibrillation type in clinic, and compared with an acute transient atrial fibrillation model, the research and application range is wider; compared with tail vein injection, intraperitoneal injection, subcutaneous pump burying and other modes, the non-creative model has the advantages that damage to small animals is smaller, and the requirement for the operation technology is low.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for improving hypoxia resistance of pelteobagrus vachelli based on hypoxia induction of liver extracellular vesicles of the pelteobagrus vachelli. The method comprises the following steps: extracting high-purity extracellular vesicles EVs in liver tissues of pelteobagrus vachelli subjected to low-oxygen treatment by adopting a method of combining differential centrifugation and high-precision iodixanol density gradient centrifugation; diluting the extracted EVs to 2mu g / mu L by using PBS (Phosphate Buffer Solution) to prepare an EVs suspension; an intraperitoneal injection mode is adopted, the EVs suspension is injected into the body of the pelteobagrus vachelli, and after injection is conducted for 24 hours, the hypoxia resistance of the pelteobagrus vachelli is evaluated through a suffocation point detection test. The invention opens up a brand new path for improving the hypoxia resistance of the pelteobagrus vachelli, provides a new idea and a new method for efficiently enhancing the hypoxia resistance of economic fishes in the field of aquaculture, is expected to play an important role in actual aquaculture production, and assists the sustainable development of the aquaculture industry.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention discloses application of adenosine deaminase or a modifier thereof in preparation of a medicine for treating diabetic nephropathy. After intraperitoneal injection treatment of polyethylene glycol modified escherichia coli expressed mouse adenosine deaminase is carried out on a mouse with diabetic nephropathy, the damage degree of the kidney of the mouse is obviously weakened. According to the invention, the adenosine deaminase or the modifier thereof has an obvious treatment effect on the type 2 diabetic nephropathy for the first time, and the adenosine deaminase and the modifier thereof have potential application prospects in preparation of the medicines for treating the type 2 diabetic nephropathy.

The invention provides preparation of a PEG-modified antibacterial peptide and application of the PEG-modified antibacterial peptide in bacterial infection, belongs to the technical field of biomedical polypeptides, and particularly relates to preparation of the PEG-modified antibacterial peptide and application of the PEG-modified antibacterial peptide in a preparation for preventing or treating diseases related to bacterial infection. The PEG modified polypeptide designed in the invention is simple and convenient to operate, low in production cost and strong in antibacterial activity, can greatly optimize the toxicity and stability of the antibacterial peptide, can be used for preventing and treating diseases caused by various microbial infections, can be applied to various drug administration modes such as spraying, intraperitoneal injection, intravenous injection, nasal drop administration, spray administration and the like, and can be used for preparing drugs for preventing and treating diseases caused by various microbial infections. The traditional Chinese medicine composition has a good treatment effect on diseases such as pneumonia caused by skin wound infection, sepsis and bacterial infection.

The invention discloses an acoustic catalyst as well as a preparation method and application thereof, and belongs to the technical field of catalysts and drug therapy. NJU-319 is selected as an acoustic catalyst, NJU-319Pt is synthesized from a porphyrinyl linker (TAPP) and a hexaphenyl triphenyl unit (HFPTP) under a solvothermal condition, and the H2 generation efficiency of NJU-319Pt can be further improved. After intraperitoneal injection, the nano-drug NJU-319Pt catalyzes H2O to be reduced into H2 under ultrasonic irradiation, and meanwhile lactic acid is oxidized into pyruvic acid. The action mechanism comprises: removing ROS and relieving oxidative stress; by inhibiting an NF-kappa B pathway, the transformation of macrophages from M1 phenotype to M2 phenotype is promoted, and inflammation is reduced; mitochondrial membrane potential is reduced, EMs cell apoptosis is induced, and focus growth is inhibited. The research provides a brand new EMs treatment strategy, combines acoustic catalysis H2 generation with lactic acid oxidation, and provides a new direction for EMs treatment research.

Provided herein are composition, systems, kits, and methods for preventing and / or treating, reversing, and / or inhibiting progression of, a neurodegenerative and / or neurological conditions and / or eye conditions (e.g., retinitis pigmentosa) by administering a plurality of nanoparticles to a subject via subcutaneous, intramuscular, or intraperitoneal injection such that the plurality of nanoparticles are taken up by lymphatic capillaries and are transported to neurological and / or eye tissue of the subject via the subject's lymphatic system, wherein the plurality of nanoparticles encapsulate, or are attached or absorbed to, at least one drug agent.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention discloses a construction method of a conditional knock-down dynactin animal model of astrocytes and an application of the animal model of the conditional knock-down dynactin animal model of the astrocytes. According to the method, a Dctn1LoxP gene knock-in mouse is hybridized with an Aldh1l1-Cre / ERT2 transgenic mouse, a target genotype mouse is obtained through three rounds of breeding, 100mg / kg Tamoxifen is continuously injected into the intraperitoneal cavity of the 2-month-old mouse for 5 days, and specific knock-down of dynactin in brain and spinal astrocytes is realized, including knockout of p150Glue and reduction of DCTN4, p50 and Arp1alpha protein levels. The model has the advantages of being high in specificity, permanent in intervention aging and capable of covering multiple life stages, the defects of a traditional model are overcome, the model can be used for researching the influence of dynactin on astrocyte neurobiological functions, a reliable tool is provided for screening related targets of nervous system diseases, and the model has important application value.

The invention relates to the technical field of laboratory devices, in particular to an intelligent intraperitoneal injection auxiliary fixing device for laboratory mice, which comprises a basic bearing module, and a mouse fixing module, a pressure monitoring module, a control module, an indication module and a power supply module which are mounted on the basic bearing module, wherein the mouse fixing module is used for fixing a mouse, the mouse fixing module comprises a lower arc-shaped latticed clamping plate, an upper arc-shaped clamping plate, a connecting piece and a hook lock, the lower arc-shaped latticed clamping plate and the upper arc-shaped clamping plate are connected through the connecting piece, and the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate are jointly matched to clamp the mouse; the abdomen of the mouse faces the lower arc-shaped latticed clamping plate, the hook lock is used for fixing the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate, the pressure monitoring module can monitor the stress condition of the mouse in real time, compressive stress or suffocation of the mouse is avoided, and animal welfare is improved.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention discloses an application of mannose in preparation of a medicine for preventing acetaminophen-induced drug-induced liver injury. The mannose with the mass concentration of 20% is used for intervening acetaminophen-induced (acetaminophen intraperitoneal injection dosage of 300mg / kg) drug-induced liver injury model animals as mice for four weeks in a free water drinking manner. Experiments show that after the mannose is fed for four weeks in advance, the serum ALT and AST levels of APAP-induced drug-induced liver injury model mice can be reduced, the serum inflammatory cytokine level can be reduced, and the pathological injury of liver tissues can be relieved, which indicates that the mannose can protect the APAP-induced drug-induced liver injury. The invention provides the application of mannose in the APAP-induced drug-induced liver injury, and a new prevention thought is provided for the APAP-induced drug-induced liver injury.

The invention discloses a method for constructing a diabetes animal model after hyperlipidemia type acute pancreatitis. The method comprises the following steps: S1, selecting male C57BL / 6N mice which are 7 weeks old, and feeding the male C57BL / 6N mice with hyperlipidemia; s2, injecting froglein into the abdominal cavity of the hyperlipemia mouse; s3, replacing drinking water of the mice with 5% sweet water, and testing fasting blood glucose and random blood glucose on the first day, the fourth day and the seventh day after the rain frog element is injected; s4, when the random blood glucose of the mouse is larger than or equal to 16.7 mmol / L or the fasting blood glucose of the mouse is larger than or equal to 11.1 mmol / L, the mouse And S5, killing the mouse with cervical vertebra dislocation, taking pancreatic tissues of the mouse, fixing the pancreatic tissues, performing HE staining, and if an acinus structure is damaged, cells are swelled and necrotic and a large number of inflammatory cells of interstitial substances are infiltrated, judging that the acute pancreatitis is molded. Meanwhile, if the conditions are met, it can be judged that the mouse is a diabetic mouse after hyperlipidemia type acute pancreatitis. The method can simulate the occurrence of diabetes mellitus after hyperlipemia type acute pancreatitis, and lays a good foundation for the research of diabetes mellitus after hyperlipemia type acute pancreatitis.

The invention discloses application of gnetum alcohol in treatment of adriamycin cardiomyopathy and diseases caused by adriamycin cardiomyopathy. The invention provides the application of the Gnetol or the pharmaceutically acceptable salt thereof in preparation of the medicine for preventing or treating diseases caused by adriamycin cardiomyopathy for the first time. The invention finds that in-vitro treatment of Gnemol can obviously inhibit rat H9C2 myocardial cell injury; when intraperitoneal injection of Gnetol is used for preventing or treating mice with adriamycin cardiomyopathy caused by intraperitoneal injection of adriamycin, the Gnetol is found to obviously relieve the adriamycin cardiotoxicity of the mice and improve the cardiac function. In-vitro and in-vivo studies find that Gnerol has a huge potential in treatment of adriamycin cardiomyopathy, and can be developed as a novel anti-adriamycin cardiomyopathy drug, thereby providing a novel approach and means for treatment of adriamycin cardiomyopathy. Meanwhile, the invention provides a brand new choice and thought for the current anti-adriamycin cardiomyopathy medicine.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

This invention discloses a method for establishing and validating a hydrogen peroxide-induced mouse autism model, relating to the field of medical biotechnology. The method for establishing the hydrogen peroxide-induced mouse autism model includes the following steps: injecting the hydrogen peroxide solution into the peritoneal cavity of pregnant mice to induce hydrogen peroxide, resulting in offspring mice with hydrogen peroxide induction, i.e., the mouse autism model. This invention uses near-peritoneal injection of hydrogen peroxide during the gestational period of the mother mouse, inducing oxidative stress in both the pregnant mother mouse and the offspring embryo through hydrogen peroxide alone, without causing a significant immune response in the mother mouse. Therefore, an oxidative stress-specifically induced ASD mouse model is formed. The resulting ASD offspring mice exhibit significant ASD phenotypes but do not show obvious motor impairment.

The invention relates to the field of medical application, in particular to application of nerve-soothing and brain-nourishing liquid to preparation of medicine for treating or preventing chronic fatigue syndrome. According to the invention, the nerve-soothing and brain-nourishing liquid is used for research on treatment or prevention of chronic fatigue syndrome for the first time. By establishing an intraperitoneal injection polyinosinic-cytidylic acid composite swimming induced CFS mouse model and a multi-factor composite stress induced CFS rat model, and by means of an exhaustive swimming experiment, a tail suspension experiment, a mechanical pain threshold, a Bannes maze and a pentobarbital sodium sleep experiment, an endocrine function, an immunologic function, skeletal muscle energy metabolism and other modes are detected, and the skeletal muscle energy metabolism can be detected. It is found that the nerve soothing and brain tonifying liquid can improve the CFS symptoms shown by mice and rats of the two models.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

The invention discloses a novel fish oxytocic as well as a use method and application thereof, and belongs to the technical field of fish oxytocic. The novel fish oxytocic takes polypeptide as a main component or an effective component, and the amino acid sequence of the polypeptide is shown as SEQ ID NO.1. After intraperitoneal injection of the novel fish oxytocic provided by the invention, the novel fish oxytocic has a remarkable oxytocic effect on zebrafish and can be applied to ovulation promotion of artificially cultured fishes; the method has important significance in reducing the adverse effect of external adverse environment on fish ovulation, reducing the condition requirements in the fish breeding process, ensuring the stable fry yield of a farm and promoting the healthy development of the fish culture industry; the provided novel fish oxytocic is polypeptide composed of eight amino acids, has no potential safety hazard to fishes and consumers, and has a wide application prospect.

The invention discloses application of Gabapentin in improvement of cognitive impairment of Alzheimer's disease. An application model is an APP / PS1 Alzheimer's disease animal model, a control group is a wild type mouse, Gabapentin granules are dissolved with normal saline and used in an intraperitoneal injection mode, the dosage of single administration is 50 mg / kg, administration is performed for 7 days each month, and then behavioral detection is performed. By detecting and analyzing the actual application result, the effect description of the Gabapentin on the improvement of the AD scene memory is obtained. When the medicine is subjected to intraperitoneal injection and administration, the excessive excitability of neurons can be reduced, the scene memory function of AD mice can be improved, a new use method of Gabapentin is expanded, and a new thought is provided for treatment of AD.

The invention discloses application of hypericin in preparation of a product for treating calcified aortic valve diseases, and belongs to the technical field of biological medicines. The present invention screens 260 mitochondrial-related compounds approved by the American Food and Drug Administration (FDA) to identify potential therapeutic agents. We employ a high content cell imaging system to assess the effects of these compounds on the expression levels of PGC-1 [alpha] and Runx2, where hypericin shows the most significant increase in the PGC-1 [alpha] / Runx2 ratio. After 52-week-old mice are subjected to western diet and intraperitoneal injection of 2.5 mg / kg hypericin once every other day, compared with a normal saline intraperitoneal injection group, the calcification degree of the valves of the mice supplemented with the hypericin is remarkably reduced after 16 weeks.